

Briakinumab Biosimilar - APC Research Grade

Briakinumab Biosimilar - Research Grade: APC

Unconjugated Product:

[Briakinumab Biosimilar - Research Grade](#)

Conjugate:

Allophycocyanin (APC)

Target:

CD30

Clone:

n/a

Isotype:

Human IgG1(E356D/M358L)-Kappa

Other Names:

Receptor tyrosine-protein kinase erbB-2, MLN 19, HER2, HER2/neu

Host:

CHO Cells

Species Reactivity:

Human

Specificity:

Detects human ErbB2.

Background:

Briakinumab is a humanized IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2. Briakinumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary).

Concentration:

0.2 mg/ml

**Formulation:**

This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Storage:

This Allophycocyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze.

Applications:

Flow Cytometry, IHC

Application Notes:

Red Laser (650 nm). Each investigator should determine their own optimal working dilution for specific applications.

Use: ichorbio's Briakinumab biosimilar is for research use only (RUO). **Isotype Control:**

[Bulk Human IgG1 Isotype Control \(IB1\) \[ICH2254\]](#)